Recently, a randomized phase III trial (ASTRUM-007) in China investigated chemotherapy with the programmed cell death protein-1 (PD-1) inhibitor serplulimab for PD-L1-positive advanced ESCC patients. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.